TOPICORT Drug Patent Profile

When do Topicort patents expire, and when can generic versions of Topicort launch?

Topicort is a drug marketed by Taro and Sun Pharma Canada and is included in ten NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has four patent family members in four countries.

The generic ingredient in TOPICORT is desoximetasone. There are seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the desoximetasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Topicort

A generic version of TOPICORT was approved as desoximetasone by PADAGIS ISRAEL on July 1^st, 2003.

Summary for TOPICORT

International Patents:	4
US Patents:	2
Applicants:	2
NDAs:	10
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	4
Patent Applications:	7,191
Drug Prices:	Drug price information for TOPICORT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TOPICORT
What excipients (inactive ingredients) are in TOPICORT?	TOPICORT excipients list
DailyMed Link:	TOPICORT at DailyMed

See drug prices for TOPICORT

See drug sales revenues for TOPICORT

Recent Clinical Trials for TOPICORT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	Phase 4
Psoriasis Treatment Center of Central New Jersey	Phase 4
Taro Pharmaceuticals USA	Phase 4

See all TOPICORT clinical trials

Pharmacology for TOPICORT

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for TOPICORT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TOPICORT	Topical Spray	desoximetasone	0.25%	204141	1	2013-12-18

US Patents and Regulatory Information for TOPICORT

TOPICORT is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taro	TOPICORT	desoximetasone	CREAM;TOPICAL	073210-001	Nov 30, 1990	AB	RX	No	Yes
Taro	TOPICORT	desoximetasone	OINTMENT;TOPICAL	074286-001	Jun 7, 1996		DISCN	No	No
Taro	TOPICORT	desoximetasone	GEL;TOPICAL	074904-001	Jul 14, 1998	AB	RX	No	Yes
Taro	TOPICORT	desoximetasone	OINTMENT;TOPICAL	018763-001	Sep 30, 1983		DISCN	Yes	No
Taro	TOPICORT	desoximetasone	CREAM;TOPICAL	073193-001	Nov 30, 1990	AB	RX	No	Yes
Taro	TOPICORT	desoximetasone	CREAM;TOPICAL	017856-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Taro	TOPICORT	desoximetasone	OINTMENT;TOPICAL	018594-001	Jan 17, 1985	AB	RX	Yes	Yes

Expired US Patents for TOPICORT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharma Canada	TOPICORT	desoximetasone	SPRAY;TOPICAL	204141-001	Apr 11, 2013	5,990,100
Sun Pharma Canada	TOPICORT	desoximetasone	SPRAY;TOPICAL	204141-001	Apr 11, 2013	8,715,624

International Patents for TOPICORT

See the table below for patents covering TOPICORT around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2609579	PREPARATION LIQUIDE STABLE COMPRENANT DE LA DESOXYMETASONE ET DU MYRISTATE ISOPROPYLIQUE A TENEUR REDUITE EN IMPURETES OXYDEES EN CAS DE STOCKAGE DE LONGUE DUREE (STABLE LIQUID DESOXIMETASONE COMPOSITIONS WITH REDUCED OXIDIZED IMPURITY)
European Patent Office	1888026	PREPARATION LIQUIDE STABLE COMPRENANT DE LA DESOXYMETASONE ET DU MYRISTATE ISOPROPYLIQUE A TENEUR REDUITE EN IMPURETES OXYDEES EN CAS DE STOCKAGE DE LONGUE DUREE (A STABLE LIQUID FORMULATION COMPRISING DESOXIMETASONE AND ISOPROPYL MYRISTATE WITH REDUCED OXIDIZED IMPURITY DURING LONG-TERM STORAGE)
Israel	187666	הרכב נוזלי ויציב של דסוקסימטאסון ואיזופרופיל מיריסטט עם רמת זיהומים מחומצנים פחותה במהלך איחסון ארוך טווח (Stable liquid formulation comprising desoximetasone and isopropyl myristate with reduced oxidized impurity during long-term storage)
World Intellectual Property Organization (WIPO)	2006130510

Last updated: July 30, 2026

TOPICORT (desoximetasone) is an established topical corticosteroid with limited late-stage exclusivity leverage in the US. Its market is shaped by genericization, payer-driven preference for lower-cost strengths and bases, and ongoing competition across steroid classes rather than brand-versus-brand dynamics. Financial trajectory is constrained by (1) early generic entry for most presentations, (2) low price tolerance for topical dermatology products, and (3) relatively narrow switching barriers because therapeutic effect is largely class-based.

TOPICORT (desoximetasone) market size, sales trend, and revenue trajectory

Executive snapshot

• Brand ownership: TOPICORT is marketed as desoximetasone topical (multiple strengths and bases historically listed under the brand).
• Core dynamic: generic competition dominates after initial brand coverage ends, with remaining value concentrated in any residual brand niches tied to specific dosage forms, strengths, or patient-use convenience.
• Financial trajectory expectation: peak sales followed by sustained decline as generics capture majority share; remaining revenue is typically “base business” rather than growth business.

What drives TOPICORT’s sales performance?

• Formulation mix and substitution: topical corticosteroids are frequently substitutable at the class level; pharmacy benefit managers often encourage generics based on acquisition cost and formulary tiers.
• Payer controls: step edits and quantity limits are common for topical steroids, with coverage steered to preferred generics and lower-cost formulations.
• Clinical positioning: desoximetasone competes with other topical steroids (medium-to-high potency categories depending on formulation). Net sales are sensitive to guideline adherence and formulary placement rather than differentiated mechanism benefits.
• Prescriber preferences: adoption tends to be inertia-based. Switching to the lowest-cost covered alternative is routine when clinical equivalence is accepted.

How does TOPICORT compare with other topical steroid brands?

Genericization risk is higher for older topical steroids than for novel systemically absorbed drugs because:

• prescribers accept class comparability,
• pharmacy substitution is straightforward,
• manufacturing and compendial equivalence pathways are established.

In practice, TOPICORT competes less against a single brand and more against:

• generic desoximetasone products,
• alternative corticosteroids in the same potency band,
• combination dermatology products (when the payer requires additional anti-infective or keratolytic components for specific indications).

---

Who manufactures TOPICORT and who sells generic desoximetasone?

Featured-snippet answer: TOPICORT is a brand name for desoximetasone topical corticosteroid; its US market is primarily served by generic desoximetasone across creams, ointments, and gels depending on local approvals and labeling.

Manufacturer and distributor structure

TOPICORT’s commercial footprint typically follows a pattern common to older topical brands:

• one or more brand holders historically marketed the product,
• multiple generic entrants later distribute desoximetasone under ANDA approvals.

Generic competitive set: what matters commercially?

For market share and pricing power, the relevant inputs are:

• which generic NDCs are on the plan’s formulary,
• whether specific bases (ointment vs cream vs gel) are preferred for coverage,
• whether insurance policies impose “product step” rules by vehicle or potency rather than by ingredient.

---

What exclusivity ended TOPICORT’s brand advantage in the US?

Featured-snippet answer: TOPICORT’s brand advantage has largely been eroded by generic entry after the expiration of relevant US patent protection and/or the conclusion of any data exclusivity tied to specific NDA/BLA reference periods. In practice, the product’s market dynamics align with an “older brand” profile where generics capture most prescriptions.

Patent-versus-regulatory exclusivity dynamics

For topical corticosteroids, exclusivity typically breaks down through:

• composition and formulation patent expiry,
• therapeutic method coverage ending or being narrow,
• generic eligibility via ANDA.

How does generic entry change prices and margins?

• Retail and PBM contracted pricing compresses quickly after multiple ANDAs.
• Brand net price erosion accelerates when:
  • at least one A-rated generic is on every major channel,
  • formularies shift to lower-cost alternatives without meaningful PA (prior authorization) requirements.

---

What is the Orange Book status of TOPICORT (desoximetasone) and its generic entry risks?

Featured-snippet answer: TOPICORT is covered by the FDA’s Orange Book under the controlling reference listed drug and related patents, but the market behavior indicates that generic desoximetasone entries are already established, which typically means residual brand coverage is limited to narrower patent or listing remnants rather than broad system-wide exclusivity.

What Orange Book listings determine for investors and litigators?

• Whether any listed patents remain active for specific dosage forms (cream, ointment, gel).
• Whether any listing is tied to:
  • formulation,
  • method of use,
  • packaging.

Generic launch risk framework

For a topical steroid with existing generic penetration, the main remaining “risk” for a brand holder is:

• continued NDC-level erosion if additional strengths or vehicles gain generic approvals,
• price compression from new low-cost supply.

---

What patents protect desoximetasone products like TOPICORT?

Featured-snippet answer: For established topical steroids like TOPICORT, the patent estate historically includes:

• composition-of-matter and/or formulation claims tied to desoximetasone,
• delivery vehicle and physical-form claims (base/vehicle),
• method-of-use claims for dermatologic conditions.

How patent scope affects commercial power

• Broad formulation patents can delay certain generic bases.
• Narrow vehicle claims may only protect specific strengths or ointment/cream variants.
• If multiple generic variants already exist, remaining patents do not usually stop competitive erosion but can delay particular NDCs.

---

What patent litigation or Paragraph IV challenges affect TOPICORT?

Featured-snippet answer: The typical market pattern for older topical corticosteroids is that early Paragraph IV events and patent litigation occurred around initial generic entry waves, with most major outcomes settled long ago. Current market dynamics are dominated by generics already present rather than active ongoing disputes.

What to monitor for remaining litigation impact

• Whether any settlement triggered:
  • delayed generic launches by NDC,
  • carve-outs for certain strengths,
  • licensing terms affecting supply availability.
• Whether any court decisions affected claim construction or patent validity for remaining listings.

---

How do settlement agreements and licensing deals influence TOPICORT market share?

Featured-snippet answer: In the topical steroid segment, settlements typically convert patent outcomes into timed or conditional generic launch terms. When multiple generic products already exist, settlement impact shows up mainly as:

• slower entry for select NDCs,
• pricing stabilization for a subset of SKUs,
• short-term channel protection rather than multi-year brand dominance.

Commercial channels where settlements matter

• PBM formularies and contracting: timing influences when PBMs add generics and switch coverage.
• Institutional dermatology procurement: preferences can persist until a new low-cost NDC is accepted.

---

What is the FDA regulatory path for generic desoximetasone versus TOPICORT?

Featured-snippet answer: Generic desoximetasone products rely on ANDA pathways referencing the approved TOPICORT reference product and demonstrating pharmaceutical equivalence and bioequivalence for topical corticosteroids as required by the regulatory framework.

What regulatory events matter to market trajectory?

• new approvals for alternate bases and strengths,
• labeling updates that influence how payers and prescribers select products,
• any restrictions or safety communications that alter prescribing volume.

---

What formulation and dosage-form variations change market performance for TOPICORT?

Featured-snippet answer: For TOPICORT, market performance tends to track vehicle preference and coverage design:

• ointment bases are often chosen for occlusive moisturizing needs,
• creams are favored where lower greasiness matters,
• gels can suit certain application preferences.

Which variations are typically easiest for generics to match?

• standardized strengths with established composition,
• vehicles with clear manufacturing processes.

How does vehicle choice affect substitution?

• pharmacy substitution is driven by:
  • NDC-level equivalence,
  • potency labeling,
  • formulary rules that may be vehicle-specific.

---

Geographic market dynamics: where does TOPICORT face the steepest competition?

Featured-snippet answer: The most competitive pressure is usually in the US and major payer markets where:

• multiple ANDAs are listed,
• PBMs drive formulary switching quickly,
• pharmacists substitute at point of sale.

What changes outside the US

• regulatory approval timing,
• local patent landscapes,
• reimbursement rules by country can slow or accelerate generic uptake.

---

Revenue exposure: what portion of TOPICORT earnings is at risk from ongoing generic entry?

Featured-snippet answer: With generics already established for desoximetasone topical steroids, remaining revenue exposure is primarily at the NDC level:

• additional generic approvals for remaining strength/vehicle combinations,
• further contraction of brand net price as wholesalers and payers renegotiate.

How to quantify “at-risk” value in practice

• compare brand NDC coverage with generic NDC counts,
• measure formulary tier placement shifts after new ANDA entries,
• monitor contracted pricing across major channels.

(Quantification requires NDC-level sales and payer data; those figures are not provided here.)

---

Key Takeaways

• TOPICORT’s market dynamics are dominated by generic desoximetasone substitution rather than brand differentiation.
• Brand financial trajectory follows an older-product pattern: peak sales followed by decline as generics capture share through formulary placement and price compression.
• Remaining leverage, if any, is concentrated in specific dosage forms or NDCs rather than broad category protection.
• Future upside is limited; future downside comes from additional SKU-level genericization and tightening payer rules.

FAQs

1. How fast do topical steroid generics erode TOPICORT net prices after ANDA approval?
2. Do TOPICORT vehicle types (ointment vs cream vs gel) materially affect formulary coverage and switching?
3. What are the main Orange Book patent listing categories for desoximetasone topical products (formulation vs method of use)?
4. How do PBM step edits for topical corticosteroids affect TOPICORT prescription volume?
5. What litigation timelines historically determine when new generic NDCs can launch for established topical brands like TOPICORT?

References

No sources were provided in the prompt, and no verifiable Orange Book, litigation docket, or sales/financial disclosures are included here.

DrugChatter Q&A for TOPICORT

Topicort lp discount card?